| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b53290ef881bc16e92cfbaf0cd9605a7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-602
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2230-0054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2210-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0068 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-91 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-06 |
| filingDate |
2006-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d6d58a27f731e22f7d28f18ae71baba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65df49f46a12aa4f4ba266ed26e3a994
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9fdcf1269824f6e4c051ca7ec6343b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d64fd04a5cdcc9c66410d32896af5faf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ea8a6a8e6262888d42d8a96720b849b |
| publicationDate |
2006-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006178734-A1 |
| titleOfInvention |
Methods of delivering anti-restenotic agents from a stent |
| abstract |
A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled, extended, and substantially linear drug release profile. The method of substantially linear extended release increases the therapeutic effectiveness of administration of a given dosage. In one example, a method of reducing restenosis includes delivering paclitaxel from a stent to an artery at a minimum release rate of 1 percent of the total dosage of paclitaxel on the stent per day throughout an entire administration period from the time of implantation of the stent until the time that substantially all the paclitaxel is released from the stent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8652506-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8349390-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9254202-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009304767-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011017346-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7842083-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8449901-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006079956-A1 |
| priorityDate |
2003-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |